Gene clues could personalize cetuximab treatment for head and neck cancer
NCT ID NCT01827956
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether certain gene variations (FCGR2A and FCGR3A) influence how well the drug cetuximab works in people with advanced upper aerodigestive tract cancers that have spread or come back. Researchers analyzed blood samples from 121 participants to look for these genetic markers. The goal was to find a way to predict which patients are more likely to benefit from cetuximab, potentially allowing for more personalized treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cetuximab
- What this could lead to
- If successful, this could help doctors predict which patients will benefit most from cetuximab, leading to more personalized treatment.
- What could go wrong
- This is a small, completed observational study that only looks at genetic markers. It does not test a new treatment, so it may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
121 people
The number who actually took part.
- Started
-
Aug 2009
- Finished
-
Dec 2013
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Squamous cell carcinomas of the upper aero-digestive tract recurrent or metastatic.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract * Patient with loco-regional extension not readily treatable * 18 years * Follow up in participant center * Patient information and consent for study participation * Patient presented in multidisciplinary meeting (RCP) in Aquitaine and for whom a treatment containing cetuximab has been proposed * Belong to a social security system Exclusion Criteria: * Pregnancy * Patient with psychological, social, family or geographical reason, who could not be treated or monitored regularly by study criteria, * Patients deprived of liberty or under guardianship or who could not give consent for study participation * Inclusion in another study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Squamous cell carcinoma of the upper aerodigestive tract are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.